Brugada Syndrome Substrate Characterization and Ablation (UNCOVERBrS)
Brugada Syndrome
About this trial
This is an interventional treatment trial for Brugada Syndrome
Eligibility Criteria
Inclusion Criteria: Symptomatic patients diagnosed with BrS-ECG pattern of types 1 and 2, both spontaneous and arising after Ajmaline tests, already implanted with an ICD. Symptomatic patients are defined as those who present ≥1 documented episode of VT / VF in the 12 months prior to enrollment. Patients eligible for ablation with 3D high-density mapping system in accordance with national guidelines, IFU and according to medical decision; Adult patients able to provide written informed consent Exclusion Criteria: Patients unable to provide written informed consent; Patients unable to guarantee their presence at future FU visits; Patients who, according to medical judgment, have a life expectancy of less than 12 months; Patients who have undergone cardiac ablation in the 90 days prior to enrollment. Patients who have had adverse events that have not been resolved after any invasive procedure; Women potentially pregnant or planning to become pregnant.
Sites / Locations
- Maria Cecilia HospitalRecruiting
Arms of the Study
Arm 1
Other
consecutive patients
20 patients clinically indicated for a endo-epicardial catheter-based mapping procedure for the treatment of ventricular tachycardia/ ventricular fibrillation substrate